Results 21 to 30 of about 2,458 (200)

Simultaneous Inhibition of PI3Kgamma and PI3Kdelta Deteriorates T-cell Function With Implications for Chronic Lymphocytic Leukemia

HemaSphere, 2023
Chronic lymphocytic leukemia (CLL) is a common and incurable B-cell malignancy. Recent therapeutic approaches that target the B-cell receptor signaling pathway include inhibition of phosphatidylinositol-3-kinase (PI3K).
Sebastian Faehling, Mariana Coelho, Alessia Floerchinger, Christof Schneider, Stephan Stilgenbauer, Peter Lichter, Martina Seiffert, Philipp M. Roessner   +7 more
doaj   +1 more source

Ford JG, Koh MJ, Lenart AW, et al. Real-world evidence of duvelisib and romidepsin in relapsed/refractory peripheral and cutaneous T-cell lymphomas. Blood Adv. 2025;9(16):4286-4305. [PDF]

Blood Advances
doaj   +2 more sources

PI3K inhibitors in chronic lymphocytic leukemia: where do we go from here?

Haematologica, 2022
Phosphatidylinositol 3-kinase (PI3K) inhibitors are effective in chronic lymphocytic leukemia (CLL). However, the severe toxicity profile associated with the first-generation inhibitors idelalisib and duvelisib, combined with the availability of other ...
Sigrid S. Skånland, Jennifer R. Brown
doaj   +1 more source

A molecular circuit linking the BCR to the NAD biosynthetic enzyme NAMPT is an actionable target in Richter syndrome. [PDF]

Blood Adv
Messana VG, Fascì A, Vitale N, Micillo M, Rovere M, Pesce NA, Martines C, Efremov DG, Vaisitti T, Deaglio S.   +9 more
europepmc   +3 more sources

Integrated safety analysis of umbralisib, a dual PI3Kd/CK1« inhibitor, in relapsed/refractory lymphoid malignancies [PDF]

, 2021
Phosphoinositide 3-kinase-d (PI3Kd) inhibitors are active in lymphoid malignancies, although associated toxicities can limit their use. Umbralisib is a dual inhibitor of PI3Kd and casein kinase-1« (CK1«).
Agajanian R., Allan J. N., Brander D. M., Burke J. M., Caimi P. F., Chavez J. C., Cheah C. Y., Cheson B. D., Davids M. S., Derenzini E., Essell J., Fenske T. S., Flinn I. W., Fonseca G., Ghosh N., Hsu Y., Jurczak W., Knopinska-Posluszny W., Lech-Maranda E., Leslie L. A., Miskin H. P., O'Connor O. A., Pagel J. M., Patel M. R., Pettengell R., Phillips T., Reeves J. A., Samaniego F., Sharman J. P., Sportelli P., Weiss M. S., Zinzani P. L.   +31 more
core   +1 more source

Roles of PI3Kγ and PI3Kδ in mantle cell lymphoma proliferation and migration contributing to efficacy of the PI3Kγ/δ inhibitor duvelisib

Scientific Reports, 2023
Mantle cell lymphoma (MCL) is an aggressive B-cell non-Hodgkin lymphoma that is incurable with existing therapies, and therefore presents a significant unmet clinical need.
Kathleen J. Till, Mariah Abdullah, Tahera Alnassfan, Gallardo Zapata Janet, Thomas Marks, Silvia Coma, David T. Weaver, Jonathan A. Pachter, Andrew R. Pettitt, Joseph R. Slupsky   +9 more
doaj   +1 more source

Targeting PI3Kδ and PI3Kγ signalling disrupts human AML survival and bone marrow stromal cell mediated protection [PDF]

, 2016
Phosphoinositide-3-kinase (PI3K) is an enzyme group, known to regulate key survival pathways in acute myeloid leukaemia (AML). It generates phosphatidylinositol-3,4,5-triphosphate, which provides a membrane docking site for protein kinaseB activation ...
Alves, Arcaro, Asou, Bouscary, Bouscary, Bouscary, Bowles, Carroll, Carroll, DiPersio, Druker, Esmaeili-Mahani, Finan, Gandhi, Giese, Gilliland, Hirsch, Johnson, Jordan, Kahl, Khwaja, Khwaja, Ko, Konopleva, MacEwan, MacEwan, Niitsu, Pettitt, Pocock, Preudhomme, Recher, Ronnstrand, Rushworth, Solary, Ulrich, Wei, Wymann, Wymann   +37 more
core   +1 more source

Circulating Th17 T cells at treatment onset predict autoimmune toxicity of PI3Kδ inhibitors

Blood Cancer Journal, 2023
PI3Kδ inhibitors are approved for the therapy of B cell malignancies, but their clinical use has been limited by unpredictable autoimmune toxicity, despite promising efficacy and evidence that toxicity is associated with improved clinical outcomes. Prior
Deepti Gadi, Stephen P. Martindale, Pui Yan Chiu, Jasneet Khalsa, Pei-Hsuan Chen, Stacey M. Fernandes, Zixu Wang, Svitlana Tyekucheva, John-Hanson Machado, David C. Fisher, Philippe Armand, Matthew S. Davids, Scott Rodig, Barbara Sherry, Jennifer R. Brown   +14 more
doaj   +1 more source

PI3Kδ and PI3Kγ isoforms have distinct functions in regulating pro-tumoural signalling in the multiple myeloma microenvironment [PDF]

, 2017
Phosphoinositide-3-kinase and protein kinase B (PI3K-AKT) is upregulated in multiple myeloma (MM). Using a combination of short hairpin RNA (shRNA) lentivirus-mediated knockdown and pharmacologic isoform-specific inhibition we investigated the role of ...
A Gutierrez, A Khwaja, B Klein, B Vick, BJ Lannutti, BZ Katz, Carla Casulo, D Chauhan, D Chauhan, D Hambardzumyan, H Ikeda, HA Dbouk, J Bladé, J Hardin, J-h Hsu, JA McCubrey, JR Brown, K Balakrishnan, K Ogawa, KH Shain, M Laplante, MA O’Connell, N Tzenaki, N Yanamandra, P Ma, R Siegel, RR Furman, RT Burke, S Roche, SA Rushworth, SA Rushworth, SEM Herman, SM Brachmann, T Hideshima, T Hideshima, T Sasaki, Y-T Tai   +36 more
core   +1 more source

Current Treatment Options in CLL [PDF]

, 2021
After impressive developments in recent years with the rise of new targeted agents, chemoimmunotherapy (CIT) only plays a minor role in the treatment of patients with chronic lymphocytic leukemia (CLL).
Bewarder, Moritz, Kaddu-Mulindwa, Dominic, Stilgenbauer, Stephan, Thurner, Lorenz   +3 more
core   +1 more source